Patent intelligence · US
US 20260055120
Bicyclic pyrimidinones as inhibitors of NOX4
Bicyclic pyrimidinones as inhibitors of NOX4
Patent details — US 20260055120
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 26, 2026
- Expiration
- Feb 21, 2046
- Applicant
- BOEHRINGER INGELHEIM INT [DE]
- CPC classes
- A61K 31/ 519 A I, A61K 45/ 06 A I, A61K/31519, A61K/4506
Quick answer
US 20260055120 (Bicyclic pyrimidinones as inhibitors of NOX4) is held by BOEHRINGER INGELHEIM INT [DE]. Status: granted. Granted Feb 26, 2026. Expires Feb 21, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BOEHRINGER INGELHEIM INT [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 519 A I, A61K 45/ 06 A I, A61K/31519, A61K/4506, A61P/116, A61P/3100
More from BOEHRINGER INGELHEIM INT [DE]
Related pharmaceutical patents in our USPTO index.
-
WO 2026114918
DÉRIVÉS DE 2-AMINO-3-CYANO THIOPHÈNE ANNELÉS SPIROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE KRAS POUR LE TRAITEMENT DU CANCER
granted -
WO 2026114957
DÉRIVÉS DE THIOPHÈNE 2-AMINO-3-CYANO SPIROCYCLIQUES ANNELÉS EN TANT QUE DÉGRADEURS DE KRAS POUR LE TRAITEMENT DU CANCER
granted -
US 20260146050
KRAS DEGRADING COMPOUNDS COMPRISING SPIROCYCLIC ANNULATED 2 AMINO-3-CYANO THIOPHENES
granted -
WO 2026109631
UTILISATION DE PROTÉINES ENGAGEANT LES LYMPHOCYTES T DANS LE TRAITEMENT DU CANCER
granted -
US 20260146049
SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER
granted -
WO 2026099754
MÉTHODE DE RÉDUCTION DE L'EXCRÉTION VIRALE, DE COLONISATION DE TISSU ET DE DÉPLÉTION LYMPHOÏDE PROVOQUÉES PAR OU ASSOCIÉES À UNE INFECTION PAR PCV2
granted -
US 20260116870
NOVEL NAV 1.1 POTENTIATORS
granted -
WO 2026082715
DÉPLÉTION DES MACROPHAGES ET VIRUS DE LA STOMATITE VÉSICULAIRE POUR LE TRAITEMENT DU CANCER
granted
Frequently asked questions
What is US patent 20260055120?
US 20260055120 (Bicyclic pyrimidinones as inhibitors of NOX4) is held by BOEHRINGER INGELHEIM INT [DE]. Status: granted. Granted Feb 26, 2026. Expires Feb 21, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 20260055120?
BOEHRINGER INGELHEIM INT [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 20260055120 expire?
Our index shows an expiration date of Feb 21, 2046 (20 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.